AWM
TXG icon

Axxcess Wealth Management’s 10x Genomics TXG Stock Holding History

Axxcess Wealth Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511K Sell
13,333
-1,369
-9% -$35.9K 0.01% 715
2026
Q1 		$312K Sell
14,702
-755
-5% -$15.1K 0.01% 335
2025
Q4 		$252K Buy
15,457
+412
+3% +$6.22K ﹤0.01% 908
2025
Q3 		$176K Buy
15,045
+1,376
+10% +$17.9K ﹤0.01% 901
2025
Q2 		$158K Buy
13,669
+536
+4% +$4.89K ﹤0.01% 856
2025
Q1 		$115K Buy
13,133
+482
+4% +$6.08K ﹤0.01% 831
2024
Q4 		$182K Sell
12,651
-2,667
-17% -$42.1K ﹤0.01% 826
2024
Q3 		$346K Buy
15,318
+4,258
+38% +$88K 0.01% 646
2024
Q2 		$215K Buy
11,060
+4,743
+75% +$124K 0.01% 769
2024
Q1 		$237K Buy
+6,317
New +$278K 0.01% 752
2022
Q2 		– Sell
-3,472
Closed -$264K – 668
2022
Q1 		$264K Sell
3,472
-898
-21% -$78.6K 0.02% 509
2021
Q4 		$651K Buy
+4,370
New +$669K 0.05% 305

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Axxcess Wealth Management's TXG Position: Q2 2026 in Review

Axxcess Wealth Management reduced its 10x Genomics (TXG) stake by 9.3% in Q2 2026, selling an estimated $35.9K and leaving 13,333 shares worth $511K. The position accounts for 0.01% of the portfolio, ranked #715.

Axxcess Wealth Management first reported a position in TXG in Q4 2021 and has held it in 12 quarters since. The position peaked at $651K in Q4 2021. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Axxcess Wealth Management held 13,333 shares of 10x Genomics worth $511K as of Q2 2026.
  • Axxcess Wealth Management sold 1,369 10x Genomics shares in Q2 2026, an estimated $35.9K.
  • 10x Genomics made up 0.01% of Axxcess Wealth Management's portfolio in Q2 2026, its #715 holding.
  • Axxcess Wealth Management first reported a position in 10x Genomics in Q4 2021 and has held it in 12 quarters since.
  • Axxcess Wealth Management's 10x Genomics position peaked at $651K in Q4 2021.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Axxcess Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.